Covid19 vaccines and related methods

Abstract

The disclosure provides viral vaccine compositions for use in treating COVID-19 in a subject to whom the compositions are administered, as well as to methods of making and using the compositions.

What is claimed is: 
     
         1 . An immunogenic composition comprising a vesicular stomatitis virus (VSV), wherein the VSV expresses a spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 
     
     
         2 . The composition of  claim 1 , wherein the VSV serotype is Indiana vesiculovirus or New Jersey vesiculovirus. 
     
     
         3 . The composition of  claim 1 , wherein the VSV is modified to replace wildtype VSV glycoprotein with the spike glycoprotein of SARS-CoV-2 (COV-S). 
     
     
         4 . The composition of  claim 1 , wherein the VSV is modified to incorporate a measles hemagglutinin gene. 
     
     
         5 . The composition of  claim 4 , wherein the measles strain is Edmonston. 
     
     
         6 . The composition of  claim 4 , wherein the hemagglutinin gene is inserted between the COV-S gene and the VSV-L gene. 
     
     
         7 . The composition of  claim 1 , wherein the VSV is modified to incorporate the SARS-CoV-2 nucleocapsid phosphoprotein (COV-N). 
     
     
         8 . The composition of  claim 7 , wherein COV-N is incorporated between the COV-S gene and the VSV-L gene. 
     
     
         9 . The composition of  claim 1 , wherein the VSV is further modified to incorporate a genetic kill switch. 
     
     
         10 . The composition of  claim 10 , wherein the genetic kill switch is inserted between the COV-S gene and the VSV-L gene. 
     
     
         11 . The composition of  claim 1 , wherein the VSV is further modified to incorporate a reporter gene. 
     
     
         12 . The composition of  claim 11 , wherein the reporter gene is selected from the group consisting of a fluorescent gene, a bioluminescent gene, and a gene related to clinical imaging modalities. 
     
     
         13 . A method for preventing or treating an infection caused by a pathogen comprising administering to a subject an effective amount of an immunogenic composition comprising a vesicular stomatitis virus, wherein the VSV expresses a spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 
     
     
         14 . The method of  claim 13 , wherein the VSV serotype is Indiana vesiculovirus or New Jersey vesiculovirus. 
     
     
         15 . The method of  claim 13 , wherein the VSV is modified to replace wildtype VSV glycoprotein with the spike glycoprotein of SARS-CoV-2 (COV-S). 
     
     
         16 . The method of  claim 13 , wherein the VSV is modified to incorporate a measles hemagglutinin gene (MV-H). 
     
     
         17 . The method of  claim 16 , wherein the hemagglutinin gene is inserted between the COV-S gene and the VSV-L gene. 
     
     
         18 . The method of  claim 13 , wherein the VSV is modified to incorporate the SARS-CoV-2 nucleocapsid phosphoprotein (COV-N). 
     
     
         19 . The method of  claim 19 , wherein COV-N is incorporated between the COV-S gene and the VSV-L gene. 
     
     
         20 . The method of  claim 13 , wherein the immunogenic composition is administered to the subject intramuscularly or via inhalation.